Lead Optimization in Discovery Drug Metabolism and Pharmacokinetics/Case study: The Hepatitis C Virus (HCV) Protease Inhibitor SCH 503034

Eitemau Tebyg

• Selection and Characterization of Hepatitis C Virus Replicons Dually Resistant to the Polymerase and Protease Inhibitors HCV-796 and Boceprevir (SCH 503034)
  gan: Flint, Mike, et al.
  Cyhoeddwyd: (2009)
• Key steps in the structure-based optimization of the hepatitis C virus NS3/4A protease inhibitor SCH503034
  gan: Madison, Vincent, et al.
  Cyhoeddwyd: (2008)
• Discovery of Narlaprevir (SCH 900518): A Potent, Second Generation HCV NS3 Serine Protease Inhibitor
  gan: Arasappan, Ashok, et al.
  Cyhoeddwyd: (2010)
• SCH 503034, a Mechanism-Based Inhibitor of Hepatitis C Virus NS3 Protease, Suppresses Polyprotein Maturation and Enhances the Antiviral Activity of Alpha Interferon in Replicon Cells
  gan: Malcolm, B. A., et al.
  Cyhoeddwyd: (2006)
• Optimizing the "drug-like" properties of leads in drug discovery
  gan: Borchardt, Ronald T., et al.
  Cyhoeddwyd: (2006.)